Soma Kalb
View detailed information about Soma Kalb, including compliance records, violations, and related data.
Person Profile
FDA investigator, Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality).
Documents (9)
- WARNING LETTER · Jiangsu Kerbio Medical Technology Group Co. · January 24, 2025
- WARNING LETTER · United Health Products, Inc. · October 4, 2024
- WARNING LETTER · CCIC Huatongwei International Inspection Co., Ltd. · January 14, 2025
- WARNING LETTER · Mid-Link Testing Company, Ltd · March 6, 2024
- WARNING LETTER · sanitation & environmental technology institute · March 15, 2024
- WARNING LETTER · Nobles Medical Technology II, Inc. · October 20, 2023
- WARNING LETTER · University of Kentucky · November 21, 2019
- WARNING LETTER · Kennedy, Philip R. · October 16, 2019
- WARNING LETTER · Steiner Biotechnology, LLC · June 28, 2019
Person Information
Name
Soma Kalb
Title
Division Director
Role
Regulatory Personnel
ID: dc303fda-2408-43d5-9790-079ec1edcb29
Get More Insights
Access our comprehensive quality intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
1.5M+ regulatory data points
Real-time compliance monitoring
Interactive analytics dashboard
Looking for more people? Our platform provides access to thousands of FDA people with advanced search and filtering capabilities.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.